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Abstract
Background:  The functions, actions, and regulation of tissue metabolism affected by the
consumption of long chain polyunsaturated fatty acids (LC-PUFA) from fish oil and other sources
remain poorly understood; particularly how LC-PUFAs affect transcription of genes involved in
regulating metabolism. In the present work, mice were fed diets containing fish oil rich in
eicosapentaenoic acid and docosahexaenoic acid, fungal oil rich in arachidonic acid, or the
combination of both. Liver and hippocampus tissue were then analyzed through a combined gene
expression- and lipid- profiling strategy in order to annotate the molecular functions and targets of
dietary LC-PUFA.
Results: Using microarray technology, 329 and 356 dietary regulated transcripts were identified
in the liver and hippocampus, respectively. All genes selected as differentially expressed were
grouped by expression patterns through a combined k-means/hierarchical clustering approach, and
annotated using gene ontology classifications. In the liver, groups of genes were linked to the
transcription factors PPAR, HNF, and SREBP-1; transcription factors known to control lipid
metabolism. The pattern of differentially regulated genes, further supported with quantitative lipid
profiling, suggested that the experimental diets increased hepatic -oxidation and gluconeogenesis
while decreasing fatty acid synthesis. Lastly, novel hippocampal gene changes were identified.
Conclusions: Examining the broad transcriptional effects of LC-PUFAs confirmed previously
identified PUFA-mediated gene expression changes and identified novel gene targets. Gene
expression profiling displayed a complex and diverse gene pattern underlying the biological
response to dietary LC-PUFAs. The results of the studied dietary changes highlighted broad-
spectrum effects on the major eukaryotic lipid metabolism transcription factors. Further focused
studies, stemming from such transcriptomic data, will need to dissect the transcription factor
signaling pathways to fully explain how fish oils and arachidonic acid achieve their specific effects on
health.
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Background
The presence and abundance of long chain polyunsaturat-
ed fatty acids (LC-PUFA) in humans diets have been the
basis of scientific investigations for decades. Studies have
yet to resolve all the mechanisms of action of LC-PUFA, in
particular the remarkable phenotypic differences between
populations that consume different quantities of fish and
fish oil in their diets [1–5]. Dietary LC-PUFA affect proc-
esses including: growth, neurological development, lean
and fat mass accretion, reproduction, innate and acquired
immunity, infectious pathologies of viruses, bacteria and
parasites; and the incidence and severity of virtually all
chronic and degenerative diseases including cancer,
atherosclerosis, stroke, arthritis, diabetes, osteoporosis,
and neurodegenerative, inflammatory, and skin diseases
[6–11]. Due to lack of mechanistic knowledge, predic-
tions for optimal intake of nutritionally important LC-
PUFA remain vague and dietary recommendations simply
relate to prevention of overt deficiency. There is not even
scientific consensus on whether LC-PUFA present in hu-
man milk should be included in infant formulas [12].
The most often cited action of n3 LC-PUFA is that they in-
duce alterations in eicosanoids by antagonizing the pri-
mary substrate of eicosanoid metabolism: arachidonic
acid (AA) [13]. Certainly, n3 LC-PUFA replace AA in cellu-
lar membranes to some extent and alter eicosanoid prod-
ucts, but is this the primary mechanism underlying the
benefits of consuming fish? The n3 LC-PUFA alter post-
prandial lipoprotein production and clearance, and lower
circulating triglyceride-rich lipoproteins [14]. N3 LC-
PUFA induce alterations in membrane properties includ-
ing ion transport, trafficking and vesicular transport, and
alter the transcription of genes encoding proteins in lipid
biosynthesis, lipid desaturation, and lipid oxidation [15–
19].
Fish oil contains, among others, docosahexaenoic acid
(DHA; 22:6n3) and eicosapentaenoic acid (EPA; 20:5n3)
as important components. The concentration of DHA in
the retina and neurological membranes suggests a specific
role for DHA in the brain. However, neither the mecha-
nism of uptake nor the precise role of DHA in the brain is
currently well understood [20]. Rigorous elimination of
DHA and its precursor 18:3n3 from animal diets leads to
limited, but significant, phenotypic effects [21]. The basic
biochemical pathway of DHA biosynthesis from its pre-
cursor 18:3n3 is still being resolved [22]. The EPA compo-
nent of fish oil is linked to anti-inflammatory, anti-
thrombotic, and generally, eicosanoid-mediated effects by
antagonizing AA metabolism.
Arachidonic acid (AA; 20:4n6), either formed from n6
precursors in mammals or obtained directly from the diet,
is believed to exert most of its biological activity via con-
version to various eicosanoids. N6 LC-PUFA, and espe-
cially AA, are also now recognized to elicit significant
physiological effects when consumed in the diet. The lack
of significant commercial sources of AA has limited the
study of this fatty acid (FA) as a dietary ingredient until
relatively recently. Due to the commercialization of fungal
biomass production to produce very high levels of AA as a
storage oil, it is now possible to study this FA.
Until recently, LC-PUFA effects on gene transcription were
thought primarily to be mediated by a single subfamily of
orphan nuclear receptors – peroxisome proliferator acti-
vated receptors (PPARs); however, it is now becoming ev-
ident that FAs can affect many different genes either via
direct interactions or indirectly through additional tran-
scription factors including hepatic nuclear-4 (HNF-4),
nuclear factor  (NF-), retinoid X receptor  (RXR),
sterol regulatory element binding protein-1c (SREBP-1c),
and liver X receptors (LXR and LXR) [17]. Indeed, the
enthusiasm for uncovering the biological pathways un-
derlying the beneficial actions of LC-PUFA has revealed a
story that is increasingly more complex than originally
supposed [23], thereby making microarray technology an
ideal platform to further decipher the many roles of these
nutritional lipids.
In the present work, mice were fed control diets adequate
in 18:2n6 and 18:3n3 but lacking LC-PUFA; or a diet en-
riched in fungal oil (FUNG) enriched in AA, the n6 elon-
gation and desaturation product of 18:2n6; or a diet
containing fish oil (FISH) enriched in 22:6n3 and 20:5n3,
the major n3 LC-PUFA elongation and desaturation prod-
ucts of 18:3n3; or a diet containing both fungal oil and
fish oil (FUNG+FISH). Thereafter, gene expression profil-
ing was performed on two organs in parallel with quanti-
tative metabolic profiling of a broad spectrum of liver FAs.
Tissues of interest were liver, the major lipid metabolizing
tissue; and brain, the major neurological tissue and prin-
cipal site for accumulation and functionality of DHA (and
other fish oil components). The hippocampus brain re-
gion was specifically chosen because of its importance in
memory and learning [24]. Liver and brain are metaboli-
cally connected organs as both AA and DHA cross the
blood brain barrier via several possible carriers. Diets were
fed for 57 days to study chronic and sustained alterations
in control of gene expression rather than acute effects.
Results and discussion
Body weight, feed intake, and incorporation of dietary LC-
PUFA into tissue membranes
Mice were fed relatively low fat diets to minimize the ac-
cretion of body fat and to avoid the confounding effects
that LC-PUFA -rich diets are known to exert on the pro-
gression of obesity. Body weight and the change in body
weight (d58 minus d1) were not affected by dietary FALipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/2
Page 3 of 23
(page number not for citation purposes)
modulation (p = 0.17). Feed intake data showed no signif-
icant differences amongst groups (classic ANOVA consid-
ering the cages and diets as cofactors; p > 0.05). There were
also no obvious differences in brain and liver weights (p >
0.05). By these criteria, differences in gene expression and
metabolic profiles described herein were judged to be
linked to the FAs present in FUNG and FISH oils on
healthy, normal weight animals.
The incorporation of 20:4n6 and 22:4n6 following feed-
ing of the AA-rich FUNG diet, and the incorporation of
20:5n3, 22:5n3, and 22:6n3 following feeding of the EPA/
DHA-rich FISH diet, into whole brain, hippocampal, and
hepatic phospholipid (PL) pools (Table 1) was further ev-
idence the diets were consumed, resulting in significant
changes to PL acyl composition. Fish oil feeding is well es-
tablished to increase n3 LC-PUFA in hepatic PL as well as
whole brain PL [18]; whereas deficiency of n3 LC-PUFA
can decrease 22:6n-3 in hippocampal PL [25]. DHA
present in the brain can be formed from precursors in the
liver or astrocytes, and intact DHA passes the blood brain
barrier via selective transport mechanisms [26]. These
data confirm that diets did result in actual increases in the
brain of the appropriate FAs and set the stage for interpret-
ing transcriptional responses observed in each organ.
Importantly, our lipid profiling data revealed that FUNG
and FISH FAs were not identically incorporated into indi-
vidual PL in the two organs studied (partly shown in Table
1), and this may affect subsequent transcription factor sig-
naling. For example, there was consistently more AA accu-
mulating in various hepatic PL than in the hippocampus
following AA feeding; and more DHA accumulated in he-
patic cardiolipin (CL) than in hippocampal CL, whereas
the reverse was true for phosphatidylserine/phosphati-
dylinositol (PS/PI). Thus, there are several explanations
for why FUNG, FISH, and FUNG+FISH feeding resulted in
different transcriptional profiles in liver and hippocam-
pus, as discussed subsequently.
Gene Expression analysis
Differentially expressed genes induced by the dietary treat-
ments were selected using a limit fold change (LFC) mod-
el, in addition to a more conventional confidence interval
test [27]. Genes that satisfied the 5% LFC model and
which lay above the 99.9% confidence interval of pooled
replicates were selected as differentially expressed. It
should also be noted that for the liver data, inter-individ-
ual variation was examined. All genes selected as differen-
tially expressed using pooled data in the liver also laid
outside the 99.0% confidence interval when compared to
individual mouse variability, thereby lending additional
confidence to the selection method used with both the liv-
er and hippocampus data. According to these criteria,
which involves examining all possible pair-wise compari-
sons between the four diets, 329 and 356 differentially ex-
pressed genes were selected in the liver and hippocampus,
respectively. In the present document, genes that are dis-
cussed are followed by parentheses indicating fold chang-
es according to the following convention: FUNG versus
Table 1: N6/N3 LC-PUFA ratios [(20:4n6 + 22:4n6)/(20:5n3+22:5n3+22:6n3)] in whole brain, hippocampus, and hepatic phospholipid 
pools. Typically, the above ratios were highest following feeding of the AA-enriched diet, lowest following feeding of the FISH diet, and 
intermediary following feeding of the combination diet. Abbreviations: SPN, sphingomyelin; PC, phosphatidylcholine; PS/PI, mixture of 
phosphatidylserine and phosphatidylinositol; PE, phosphatidylethanolamine; CL, cardiolipin. 20:4, 20:4n6; 22:4, 22:4n6; 20:5, 20:5n3; 
22:5, 22:5n3; 22:6, 22:6n3.
Dietary Group Tissue (20:4+22:4)/(20:5+22:5+22:6) ratio in various phospholipids
SPN PC PS/PI PE CL
Control Whole Brain - 1.31 0.53 0.75 1.18
FUNG Whole Brain - 2.33 0.68 0.94 0.73
FISH Whole Brain - 0.99 0.41 0.50 0.36
FUNG +FISH Whole Brain - 1.20 0.50 0.67 1.08
Control Hippocampus - 2.96 0.50 0.79 1.30
FUNG Hippocampus - 4.18 0.67 0.96 1.09
FISH Hippocampus - 1.86 0.44 0.51 0.76
FUNG +FISH Hippocampus - 2.45 0.52 0.62 0.92
Control Liver 0.83 2.14 8.02 2.00 0.69
FUNG Liver 1.91 9.73 12.51 3.53 1.97
FISH Liver 0.32 0.32 1.52 0.35 0.16
FUNG +FISH Liver 0.90 1.48 2.93 0.62 0.39Lipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/2
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control diet, FISH versus control diet, and FUNG+FISH
versus control diet, e.g. G6pc (1.1, 1.6*, -1.9*). Those fold
changes that are significant by the 5% LFC model are fur-
ther identified with an asterisk (*). It is important to note
that the nature of the LFC model allows differentially ex-
pressed genes to be selected based on differences between
the treatments, and therefore explains why some genes
discussed in the text have no fold changes marked with an
asterisk (as significance was observed between treatments
and not versus the control diet). All liver genes discussed
in the present manuscript are found in Figure 1 (green
dots) and lie within the range of validation data (black
squares). The high degree of concordance between RT-
PCR and microarray data (86%- reported in detail else-
where [27]) establishes a certain level of confidence in the
results discussed throughout this manuscript.
To understand the trends in transcriptional response with-
in and between the two organs studied, genes were anno-
tated using GO classifications; a dynamic, structured, yet
precisely defined system which characterizes genes based
on defined categories of molecular function, biological
process, and cellular component [28]. Since the GO clas-
sifications contain several thousand descriptors, many dif-
ferentially expressed genes had a unique annotation.
Record counts for most GO identifiers were not high, al-
though a number of significant trends were observable.
Venn diagrams were constructed for the top 10 GO de-
scriptors for each category, according to record count, to
Figure 1
Graphical representation of the trend and spread of the hepatic microarray data. Blue dots indicate the highest
fold change for each probe set on the Affymetrix Mu11K chip, where the highest fold change was identified by examining all
fold changes in every possible pairwise comparison between diets. Those probe sets that were identified as absent (by Affyme-
trix software) across all dietary treatments were treated as unchanged and therefore not considered in the limit fold change
(LFC) selection model. The trend within this dataset indicates that as absolute expression increases (along the x-axis), fold
changes decrease, i.e. the chance of seeing large fold changes with highly expressed genes is minimal. The 5% LFC line of best fit
(red line) takes this observed trend into account and identifies the upper 5% of those probe sets with the greatest fold changes
within predefined bins (model parameters fully explained in [27]). The 329 probe sets that lie above the 5% LFC line are those
genes defined as differentially regulated. Green circles represent the hepatic genes discussed in the current manuscript and
black squares represent those genes validated by real time PCR. When examining the spread of the genes discussed and vali-
dated, it is apparent that genes were selected across the entire range of absolute values and not concentrated in one area. Fur-
thermore, as the validation data (which had 86% concordance with microarray data; see [27]) lies across the entire range of
absolute expression levels, a high degree of confidence is established for the genes discussed within the present manuscript.Lipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/2
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visualize broad transcriptional responses induced by die-
tary LC-PUFA (Figure 2). The interpretation of transcrip-
tomic data, especially that stemming from a nutritional
study such as this, benefits greatly from such a classifica-
tion system. The diverse whole-body effects of LC-PUFA
render individual gene interpretation difficult; however,
considering groups of genes reveals preliminary informa-
tion concerning the biological mechanisms responding to
the addition of dietary LC-PUFA.
The GO analysis and specific gene expression patterns
were interpreted to indicate that LC-PUFA-enriched oils
affected liver metabolism through the regulation of genes
directly involved in FA metabolism and lipid binding/
transport (Figure 2), as previously reported in rats [18].
When examining GO classifications for the hippocampus,
such descriptors as cell signaling and cell cycle control are
seen in response to dietary LC-PUFA. This result was ex-
pected, as the two organs have very different biochemical
roles and import dietary FA via distinctly different means.
The tissue functions were reflected in the transcriptomic
profile. Although there were relatively few overlapping
functions between the two organs, the most prominent
overlapping function indicated that LC-PUFA was affect-
ing genes related to transcription and DNA/RNA-binding.
Hepatic gene expression analysis and transcription factor 
signatures
It is difficult to interpret transcriptional profiling data
alone, since dimerization, post-translational modifica-
tions, relative quantities of co-activators and co-repres-
sors, and the formation of multiple transcriptional
complexes binding to common promoter regions ulti-
mately determines the binding activation potential of
transcription factors. Nevertheless, clustering analysis of
differentially regulated genes revealed numerous genes
known to be regulated by specific transcription factors,
thereby enabling several transcription factor signatures to
be established. These signatures then provide clues con-
cerning the various pathways through which FA may effect
gene transcription. Additionally, FUNG and FISH diets
regulated some transcription factors not (Table 2) previ-
Figure 2
Venn diagrams depicting the top 10 GO functional categories in the hippocampus and liver. Examining the top 10
GO classifications for cellular component (CC), biological process (BP), and molecular function (MF) indicated that functional
commonalties (overlapping circles) in response to LC-PUFAs exist between the two organs, implying that molecular responses
to dietary LC-PUFA occurs via common biological pathways rather than through identical genes. Additional organ-specific func-
tions are also indicated (individual circles).Lipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/2
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Table 2: Differentially expressed genes in response to dietary LC-PUFAs in (A) hippocampus and (B) liver. Table includes gene catego-
ries discussed in the manuscript. Genes are grouped by functional category, sorted alphabetically, and annotated with NCBI LocusLink. 
Average difference intensity (ADI) represents gene absolute expression, and was used to calculate fold changes. Differentially expressed 
genes were clustered with a combined k-means/hierarchical approach. Asterisk (*) indicates ADIs significantly different from control 
diet, using 5% LFC gene selection model equations (LFChippocampus = 1.36 + (90/min ADI); LFCliver = 1.52+(100/min ADI)).
(A)
Gene Sym-
bol
Description Unigene ADI
 (Average Difference Intensity)
Cluster 
Coordi-
nates
Control FUNG FISH
FUNG
+
FISH
Nucleic Acid Binding
Ar androgen receptor Mm.4470 83 209* 136 101 H1-K2
Atoh4 atonal homolog 4 (Drosophila) Mm.42017 21 97 74 119* H1-K2
Btf3 basic transcription factor 3 Mm.1538 992 522* 475* 877 H5-K5
Dbp D site albumin promoter binding protein Mm.3459 111 206 84 154 H1-K2
Ddb1 damage specific DNA binding protein 1 Mm.29623 239 299 242 139 H4-K4
Dscr1 Down syndrome critical region homolog 1 (human) Mm.56 304 258 138* 130* H5-K3
E2f3 E2F transcription factor 3 Mm.6333 110 55 214 80 H3-K1
Elk1 ELK1, member of ETS oncogene family Mm.3064 613 425 690 402 H3-K1
Hdac1 
(Rpd3)
high homology to histone deacetylase 1 Mm.2602 393 231 411 353 H3-K1
Hoxd12 homeo box D12 Mm.57124 436 368 403 234* H4-K4
Idb1 inhibitor of DNA binding 1 Mm.444 148 169 344* 238 H3-K1
Idb3 inhibitor of DNA binding 3 Mm.110 41 117 156* 138 H1-K2
Nhlh1 nescient helix loop helix 1 Mm.2474 111 198 79 132 H1-K2
Pax9 paired box gene 9 Mm.5035 104 20 165 77 H3-K1
Pcbp3 poly(rC) binding protein 3 Mm.143816 187 180 52* 184 H5-K5
Purb purine rich element binding protein B Mm.154651 391 313 172* 246 H5-K3
Lipoprotein Metabolism
Apod apolipoprotein D Mm.2082 325 423 575* 456 H3-K1
Miscellaneous Genes
Htr4 5 hydroxytryptamine (serotonin) receptor 4 (5-HT) Mm.20440 20 130* 76 89 H1-K2
Pomc proopiomelanocortin Mm.21878 51 304* 80 71 H1-K2
Prkcd protein kinase C, delta (PKC) Mm.2314 461 297 353 263* H5-K3
Siat8e sialyltransferase 8 (alpha 2, 8 sialytransferase) E Mm.5173 128 207 49 20* H5-K4
Ttr transthyretin Mm.2108 304 490 157* 687* H1-K5
(B)
Gene Sym-
bol
Description Unigene ADI
 (Average Difference Intensity)
Cluster 
Coordi-
nates
Control FUNG FISH
FUNG
+
FISH
Nucleic Acid Binding
Atf4 activating transcription factor 4 Mm.641 1122 910 1045 647 H1-K4
Atf5 activating transcription factor 5 Mm.1566 870 505* 563* 281* H3-K3
Dbp D site albumin promoter binding protein Mm.3459 169 581* 174 747* H5-K5
Eef1a1 eukaryotic translation elongation factor 1 alpha 1 Mm.196614 1517 845* 1877 1642 H1-K1
Eif4a1 eukaryotic translation initiation factor 4A1 Mm.12858 125 180 68 218 H5-K5Lipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/2
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Ercc2 excision repair cross-complementing rodent repair 
deficiency, complementation group 2
Mm.56990 148 142 319* 298* H1-K1
Gtf2i general transcription factor II I Mm.22593 89 47 150 20 H1-K1
HNF-3g forkhead box A3 (Foxa3) Mm.42260 411 501 454 207* H2-K4
Hoxd12 homeo box D12 Mm.57124 127 177 85 44 H2-K4
Hzf-pending hematopoietic zinc finger Mm.14099 235 328 516* 173 H1-K4
Klf13 Kruppel-like factor 13 Mm.41170 257 455 381 515* H4-K2
Miz1 Msx-interacting-zinc finger Mm.6370 283 453 429 146 H2-K4
Nfyb nuclear transcription factor-Y beta (NF-Y) Mm.3259 121 219 73 195 H4-K2
Pbx1 pre B-cell leukemia transcription factor 1 Mm.61526 1587 1039 1328 933* H3-K3
Rpo2tc1 RNA polymerase II transcriptional coactivator Mm.41746 461 560 368 292 H2-K4
Srebp-1 ethanol induced 6 (sterol regulatory element binding 
protein-1); Etohi6
Mm.30133 648 610 310* 370* H3-K3
Tceb1l transcription elongation factor B (SIII), polypeptide 1 
(15 kDa),-like
Mm.42944 420 549 672* 744* H5-K5
Tcf2 transcription factor 2 Mm.7226 151 121 244 20* H1-K4
Tcf7 transcription factor 7, T-cell specific Mm.31630 212 237 203 568* H5-K5
Tcfe3 EST highly similar to transcription factor E3 Mm.25762 114 135 203 20 H1-K4
Thrsp; 
Spot14
thyroid hormone responsive SPOT14 homolog (Rat-
tus)
Mm.28585 2481 2947 2353 1505* H2-K4
Usf2 upstream transcription factor 2 Mm.15781 180 209 32* 191 H5-K2
Fatty Acid Synthesis
Acas1 acetyl-Coenzyme A synthetase 1 (AMP forming) Mm.22719 497 200* 297* 113* H3-K3
Acly ATP citrate lyase (ACL) N/A 2513 939* 1117* 530* H3-K3
Acly ATP citrate lyase (ACL) N/A 3197 1568* 1754* 878* H3-K3
Acly ATP citrate lyase (ACL) N/A 456 115* 64* 51* H3-K3
Acly ATP citrate lyase (ACL) N/A 603 278* 252* 163* H3-K3
Elovl2; Ssc2 elongation of very long chain fatty acids (FEN1/Elo2, 
SUR4/Elo3, yeast)-like 2
Mm.2567 3010 2291 1780* 1690* H3-K3
Elovl3; Cig30 elongation of very long chain fatty acids (FEN1/Elo2, 
SUR4/Elo3, yeast)-like 3
Mm.21806 517 421 983* 317 H1-K1
Facl2 fatty acid Coenzyme A ligase, long chain 2 Mm.28962 514 709 677 926* H5-K5
Fasn fatty acid synthase (FAS) Mm.3760 5214 2715* 4104 966* H1-K5
Scd1 stearoyl-Coenzyme A desaturase 1 Mm.140785 9783 8749 9493 5541* H1-K4
Fatty Acid Oxidation
Acadm acetyl-Coenzyme A dehydrogenase, medium chain 
(MCAD)
Mm.10530 1364 2014 1774 2261* H4-K2
Aldh1a1 aldehyde dehydrogenase family 1, subfamily A1 Mm.4514 2387 3917* 4274* 4091* H4-K2
Aldh1a7 aldehyde dehydrogenase family 1, subfamily A7 Mm.14609 1717 1977 3208* 2264 H1-K1
Cpt1a carnitine palmitoyltransferase 1, liver Mm.18522 734 1285* 1058 1272* H4-K2
Cpt2 carnitine palmitoyltransferase 2 Mm.29499 418 673 791* 690* H4-K1
Crat carnitine acetyltransferase Mm.20396 58 82 190* 71 H1-K1
Ech1 enoyl coenzyme A hydratase 1 (delta 3,5-delta 2,4-
dienoyl-CoA isomerase)
Mm.2112 1239 1388 2031* 1731 H1-K1
Carbohydrate Metabolism
Camk2b calcium/calmodulin-dependent protein kinase II, beta Mm.4857 152 139 20* 84 H3-K3
Cam-Pde 1c calcium/calmodulin-dependent 3',5'-cyclic nucleotide 
phosphodiesterase 1c
N/A 98 61 75 584* H5-K5
G6pc glucose-6-phosphatase, catalytic (G6Pase) Mm.18064 1065 1224 1669* 553* H1-K4
Got1 glutamate oxaloacetate transaminase 1, soluble Mm.19039 976 798 656 467* H3-K3
Gpam glycerol-3-phosphate acyltransferase, mitochondrial 
(GPAT)
Mm.87773 1184 683* 989 526* H3-K4
Hspa5 heat shock 70kD protein 5 (glucose-regulated protein, 
78kD)
Mm.918 2802 1996 3014 1820* H1-K4
Pck1 phosphoenolpyruvate carboxykinase 1, cytosolic 
(PEPCK)
Mm.42246 1376 2913* 2198* 2369* H4-K2
Pck1 phosphoenolpyruvate carboxykinase 1, cytosolic 
(PEPCK)
Mm.42246 964 1550 1352 1652* H4-K2
Pck1 phosphoenolpyruvate carboxykinase 1, cytosolic 
(PEPCK)
Mm.42246 243 647* 452* 633* H4-K2
Table 2: Differentially expressed genes in response to dietary LC-PUFAs in (A) hippocampus and (B) liver. Table includes gene catego-
ries discussed in the manuscript. Genes are grouped by functional category, sorted alphabetically, and annotated with NCBI LocusLink. 
Average difference intensity (ADI) represents gene absolute expression, and was used to calculate fold changes. Differentially expressed 
genes were clustered with a combined k-means/hierarchical approach. Asterisk (*) indicates ADIs significantly different from control 
diet, using 5% LFC gene selection model equations (LFChippocampus = 1.36 + (90/min ADI); LFCliver = 1.52+(100/min ADI)). (Continued)Lipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/2
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ously associated with these dietary oils, thereby indicating
novel LC-PUFA mediated molecular mechanisms of ac-
tion. These include: Spot14 (Thrsp), transcription factor 7
T-cell specific (Tcf7), transcription factor 2 (Tcf2), nuclear
transcription factor-Y (NF-Y ; Nfyb transcript), D site al-
bumin promoter binding protein (Dbp), general tran-
scription factor II (Gtf2I), activating transcription factor 5
(Atf5), Msx-interacting-zinc finger (Miz1), and pre B-cell
leukemia transcription factor 1 (Pbx1). In the present
work, the focus will be on transcription factors previously
identified as mediators of LC-PUFA actions, such as
PPARs, SREBP, and HNFs.
Hepatic peroxisome proliferator-activated receptors 
(PPARs)
PPARs are nuclear hormone receptors that are activated by
micromolar concentrations of various FAs and FA ana-
logues, such as fibrates and thiazolidinediones [29]. This
subfamily can be divided into three isotypes, designated
PPAR, PPAR and PPAR, each with tissue-specific ex-
pression. PPARs form heterodimers with retinoid X recep-
tor (RXR), and interact with the peroxisome proliferator
response element (PPREs) in gene promoters. PPREs are
direct repeats (DR) of a hexanucleotide sequence AGGT-
CA separated by one nucleotide and are therefore referred
to as a DR-1 response element [30]. PPAR and PPAR
play critical roles in the catabolism and storage of FA,
whereas the function of PPAR is less certain. PPAR is the
predominant PPAR subtype expressed in liver, as con-
firmed presently. The other two subtypes were not likely
expressed in the mouse liver, as negative values were ob-
tained with the Affymetrix software. PPAR is reported to
regulate genes involved in FA transport, synthesis and ox-
idation, glucose and lipid metabolism, ketogenesis and
5, 6, and 9-desaturation [17].
In spite of dramatic differences in the expression of a vari-
ety of PPAR-responsive genes, PPAR gene expression itself
Pck1 phosphoenolpyruvate carboxykinase 1, cytosolic 
(PEPCK)
Mm.42246 320 660* 564* 744* H4-K2
Cytochrome P450 Metabolism
Cyp1a2 cytochrome P450, 1a2, aromatic compound inducible Mm.15537 3952 5021 2839* 4187 H2-K2
Cyp2a4 cytochrome P450, 2a4 Mm.14781 922 2682* 1100 2362* H4-K2
Cyp2b9 cytochrome P450, 2b9, phenobarbitol inducible type a Mm.876 57 161 241* 146 H4-K1
Cyp3a11 cytochrome P450, steroid inducible 3a11 Mm.21193 4777 7297 8429* 6542 H4-K1
Cyp3a16 cytochrome P450, 3a16 Mm.30303 1438 2805* 2835* 2282* H4-K2
Cyp4a10 cytochrome P450, 4a10 Mm.10742 335 894* 1566* 1010* H4-K1
Cyp4a14 cytochrome P450, 4a14 Mm.7459 20 160* 385* 51 H1-K1
Cypf13 cytochrome P450 CYP4F13 Mm.22045 600 834 529 439 H2-K2
Por P450 (cytochrome) oxidoreductase Mm.3863 54 208* 119 232* H4-K2
Transport
Abca1 ATP-binding cassette, sub-family A (ABC1) member 1 Mm.369 550 121* 217* 270* H3-K3
Abca7 ATP-binding cassette, sub-family A (ABC1) member 7 Mm.103351 20 20 20 144* H5-K5
Abce1 ATP-binding cassette, sub-family E (OABP)member 1 Mm.5831 118 116 310* 124 H1-K1
Cd36 CD36 antigen Mm.18628 247 223 591* 170 H1-K1
Fabp5 fatty acid binding protein 5, epidermal (E-FABP) Mm.741 3236 593* 384* 238* H3-K3
Slc10a1 solute carrier family 10 (sodium/bile acid cotrans-
porter family), member 1 (Ntcp)
Mm.104295 845 877 534* 1005 H5-K5
Sterol Metabolism
Fpps farnesyl pyrophosphate synthase Mm.39472 794 327* 510* 421* H3-K3
Hmgcs2 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2, 
mitochondrial (HMG-CoA2)
Mm.10633 3592 4491 4590 5822* H5-K5
Lipoprotein Metabolism
Apoa4 apolipoprotein A-IV Mm.4533 2011 781* 629* 117* H3-K3
Apoa4 apolipoprotein A-IV precursor Mm.4533 194 60* 46* 20* H3-K3
ApoB-100 EST highly similar to apolipoprotein B-100 precursor Mm.29123 2675 5710* 5005* 5395* H4-K2
Apoc1 apolipoprotein CI Mm.182440 5719 3465* 6337 5953 H1-K1
Apoc2 apolipoprotein CII Mm.28394 3199 2511 2143* 2005* H3-K3
Apoe apolipoprotein E Mm.138866 6425 6438 9632* 5253 H1-K1
Table 2: Differentially expressed genes in response to dietary LC-PUFAs in (A) hippocampus and (B) liver. Table includes gene catego-
ries discussed in the manuscript. Genes are grouped by functional category, sorted alphabetically, and annotated with NCBI LocusLink. 
Average difference intensity (ADI) represents gene absolute expression, and was used to calculate fold changes. Differentially expressed 
genes were clustered with a combined k-means/hierarchical approach. Asterisk (*) indicates ADIs significantly different from control 
diet, using 5% LFC gene selection model equations (LFChippocampus = 1.36 + (90/min ADI); LFCliver = 1.52+(100/min ADI)). (Continued)Lipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/2
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was quite constant in all mice analyzed, as previously re-
ported [31]. This constancy of PPAR expression indicates
that differences in the transcription of genes containing a
PPRE are likely due to the direct activation of PPARs. Feed-
ing our diets affected various genes containing a PPRE,
with roles in triacylglycerol synthesis (mitochondrial glyc-
erol-3-phosphate acyltransferase, Gpam), FA oxidation
(carnitine palmitoyl transferase, Cpt1; dienoyl CoA iso-
merase, Ech1), FA desaturation (stearoyl-coenzyme A de-
saturase, Scd1 or 9 desaturase), gluconeogenesis
(cytosolic phosphoenolpyruvate carboxykinase 1, Pck1 or
PEPCK; glucose-6-phosphatase, G6pc), cytochrome p450
metabolism (Cyp4a-10 and -14), FA transport (Cd36; FA
binding protein, Fabp5), cholesterol metabolism and
transport (apolipoprotein A4, Apoa4; apolipoprotein B-
100, ApoB-100), and ketone body formation (mitochon-
Table 3: Ratios of FA with n+2 carbons/FA with n carbons in the diet and various hepatic PL pools. There was some evidence to indicate 
elongase activity may have been impaired in some cases, as explained in the text. n, refers to the number of carbons in the FA chain 
length; Eth, Ether; refer to previous Tables for other abbreviations. Groups sharing a superscript in common are not statistically signif-
icant, ANOVA, P < 0.05.
Dietary 
Group
16:0/
14:0
18:0/
16:0
20:0/
18:0
22:0/
20:0
24:0/
22:0
18:1n
7/
16:1n
7
20:1n
9/
18:1n
9
22:1n
9/
20:1n
9
24:1n
9/
22:1n
9
20:2n
6/
18:2n
6
22:2
n6/
20:2
n6
20:3n6
/
18:3n6
20:3n
3/
18:3n
3
20:4n
3/
18:4n
3
22:4n6/
20:4n6
22:5n3/
20:5n3
Eth
18:0
/
16:0
Diet 
ratio
Control 12.60 0.29 0.06 1.57 0.32 0.00 0.00 0.00 0.00 0.00 - 0.00 - - 0.00 0.00 0.29
FUNG 13.57 0.33 0.08 0.96 4.10 0.00 0.00 0.00 0.00 0.01 - 1.63 - - 0.01 0.00 0.33
FISH 8.95 0.29 0.09 0.91 1.14 0.00 0.01 0.44 1.75 0.01 - 0.43 - - 0.05 0.37 0.29
FUNG+F
ISH
9.61 0.32 0.10 0.71 4.00 0.00 0.01 0.36 2.38 0.02 - 1.22 - - 0.01 0.29 0.32
SPN
Control - 0.26a 0.43b 5.99a 0.47b 1.02c ---- - 0 . 2 3 a -- 0 . 0 0 a 0.40a -
FUNG - 0.33b 0.40b 7.89b 0.49b 0.54ab ---- - 0 . 1 5 a - - 0.18b 0.39a -
FISH - 0.37b 0.23a 7.49a
b
0.37a 0.91bc ---- - 0 . 4 5 b -- 0 . 0 0 a 0.99b -
FUNG+F
ISH
-0 . 3 4 b 0.38b 9.72c 0.43ab 0.36a ---- - 0 . 2 5 a -- 0 . 0 0 a 0.32a -
PC
Control 141.6
1a
0.34b 0.02a 0.17b -2 . 2 9 d 0.02b 0.08a -0 . 0 2 b - 10.79b -0 . 5 1 c 0.02b 0.61b -
FUNG 162.3
6b
0.35b 0.01a 0.22b -1 . 8 2 c 0.02b 0.11ab -0 . 0 1 a -4 . 8 1 a -0 . 0 4 a 0.02b 1.98c -
FISH 191.3
1c
0.26a 0.02a 0.14a -1 . 2 4 b 0.02b 0.14b -0 . 0 2 b - 19.56c -0 . 7 3 d 0.01a 0.12a -
FUNG+F
ISH
216.9
5d
0.26a 0.02a 0.10a -0 . 9 8 ab 0.01a 0.23c -0 . 0 1 a -7 . 6 6 ab -0 . 1 7 ab 0.01a 0.69b -
PS/PI
Control 10.65
a
5.57c 0.01a 0.29b 0.58b -0 . 0 7 b 0.35a 0.99ab 0.08c 0.86
c
5.68a - - 0.02b 0.40a -
FUNG 32.30
b
4.96b
c
0.01a 0.31b 0.41ab -0 . 0 6 a 0.50ab 1.14b 0.05ab 0.39
b
4.73a - - 0.02b 2.41b -
FISH 17.66
a
4.41a
b
0.02b 0.15a 0.31a -0 . 0 6 a 0.36a 0.56a 0.05ab 0.37
ab
14.63b - - 0.02b 0.58a -
FUNG+F
ISH
42.49
b
3.83a 0.02b 0.16a 0.35a -0 . 0 7 b 0.84b 0.57a 0.03a 0.23
ab
6.18a -- 0 . 0 1 a 1.61ab -
PE
Control 82.93
a
0.80a 0.01a 0.18c -3 . 0 2 c 0.05b 0.16a -0 . 0 2 a 0.00
a
4.70b 0.12a 0.047a 0.02b 43.94c 0.38
d
FUNG 120.3
6b
0.92c 0.01a 0.13b
c
-2 . 1 9 b 0.04a 0.15a -0 . 0 3 b 0.00
a
3.10a 0.00a 0.174a 0.04c 121.04d 0.59c
FISH 141.6
9b
0.71b 0.02b 0.10a
b
-1 . 4 9 a 0.05a 0.18a -0 . 0 2 a 0.29
b
6.78c 0.11a 0.793b 0.01a 3.98a 0.33
b
FUNG+F
ISH
137.1
8b
0.78a
b
0.02b 0.08a -1 . 2 3 a 0.05a 0.32b -0 . 0 3 b 0.10
a
3.06a 0.35b 0.134a 0.02b 22.62b 0.53a
b
CL
Control 4.14a 0.84a
b
0.08b 0.32a -1 . 4 4 b 0.05b 0.14a 1.87c 0.01a 0.00
a
5.80a 0.00a - 0.09b --
FUNG 4.58b 0.66b 0.06a 0.72b -1 . 0 6 a 0.04a 0.51b 0.59a 0.01a 0.03
b
15.91b 0.22b -0 . 0 9 b --
FISH 5.69b
c
1.09a 0.08b 0.21a -1 . 4 5 b 0.05b 0.11a 1.15ab 0.01a 0.00
a
7.20ab 0.26b -0 . 0 5 a --
FUNG+F
ISH
6.70c 1.02a 0.09c 0.33a -1 . 3 9 b 0.05b 0.50b 0.66a 0.01a 0.01
ab
15.38b 0.42c -0 . 0 5 a --Lipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/2
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drial 3-hydroxy-3-methylglutaryl-coenzyme A synthase 2,
Hmgcs2).
Various genes involved in cholesterol metabolism (micro-
somal transfer protein, MTP; apolipoprotein C3, Apoc3;
cholesterol 7 hydroxylase, Cyp7a1), carbohydrate me-
tabolism (pyruvate kinase; facilitative glucose transporter
gene, GLUT2), and coagulation (vitamin K dependent co-
agulation factors VII, IX, X) have been previously found to
be induced by PPARs [32], but were not transcriptionally
regulated in the present experiment.
A recent study examined effects of PPAR-specific induc-
tion in murine livers using cDNA microarrays [30]. De-
spite the different strain of mice examined (C57BL/6J)
and the different genomic technology utilized for the ex-
amination of differentially expressed genes (cDNA micro-
arrays), several genes were found differentially regulated
in both experiments, indicating that the PPAR agonist and
LC-PUFA affect gene expression through similar path-
ways. Genes such as Cd36, Cyp2b9, Hmgcs2, and Ech1
were induced more than 4-fold when Wy-14,643 (a PPA-
R-specific agonist) was administered to mice for 2 weeks.
These transcripts were similarly regulated in the current
study, providing further indication that many of the dif-
ferentially expressed genes were likely PPAR-activated.
Preliminary evidence suggests preferred ligands for PPAR
activation are 18 C and 20 C FAs, as FAs shorter than 14 C
or longer than 20 C will not fit correctly into the PPAR
binding pocket and stabilize the AF-2 helix [17]. The net
effect would be that PPAR co-activators are not recruited
to relax nucleosomal DNA and allow transcription ma-
chinery to interact with various promoter elements. There-
fore DHA (22:6:n3) may require retroconversion via -
oxidation to an 18 C or 20 C LC-PUFA prior to activating
PPARs [17,33]. Without the use of purified FA it is difficult
to distinguish whether the DHA in our fish oil preparation
was retroconverted since the fish oil also provided the ret-
roconversion products, 20:5n3 and 22:5n3 (Table 3).
Likewise, AA was not provided as a pure FA component
making comparisons to the control to detect retroconver-
sion difficult. However, earlier work clearly shows that
both DHA and AA can be retroconverted to 2 carbon
shortened intermediates.
Hepatic sterol regulatory element-binding proteins (SREB-
Ps)
SREBPs are critically important basic helix-loop helix
(bHLH) transcription factors activated in response to var-
iations in intracellular cholesterol levels that induce tran-
scription of genes with sterol regulatory element (SRE)
and E-box containing promoters. Within the SREBP pro-
moter element, the liver X receptor (LXR)-responsive ele-
ments (LXRE) may have an important role [34]. LC-PUFA
may affect SREBP-1c mediated transcription via several
mechanisms. One mechanism is to antagonize activation
of the LXR receptor leading to fewer LXR/RXR heterodim-
er complexes to bind the LXRE in the SREBP-1c promoter
and less SREBP-1c-mediated transcription of SRE-contain-
ing genes [34]. The PPAR signaling cascade intertwines
with SREBP pathways since LC-PUFA also activate PPAR,
which can induce LXR expression [17].
In the present experiment, saturated FA replaced AA and
DHA to equilibrate total fat content. Yoshikawa et al.[34]
found AA to be more potent than DHA (saturated and
monounsaturated being ineffective) at inhibiting activa-
tion of SREBP-1c promoter and LXRE enhancer con-
structs, induced by co-expression of LXR or -. An
increase in transcription of SREBP-1 may be associated
with increased levels of the active SREBP-1 protein.
Numerous hepatic genes containing SRE promoters were
regulated by LC-PUFA in the present experiments, includ-
ing SREBP-1 itself (consistent with [35,36]). Also regulat-
ed were genes involved in triacylglycerol synthesis
(Gpam), FA synthesis and elongation (Acas1, Acly, FA
synthase, Spot14, Elovl2; Elovl2 may speculatively con-
tain an SRE as described by Moon and colleagues [35]), FA
desaturation (Scd1), gluconeogenesis (Pck1), cytochrome
p450 metabolism (Cyp4a-10 and -14), FA transport
(Cd36), cholesterol metabolism and transport (Fpps),
and ketone body formation (mitochondrial Hmgcs2). It is
evident that genes containing a PPRE have roles in FA ox-
idation but not FA synthesis, whereas the converse is true
for genes containing SRE promoters.
Several genes that may contain SRE promoters such as
SREBP-1 and Acly, and Elovl2 and Cd36, were found in
the same cluster. However, similar to PPRE-containing
genes, not all SRE-containing genes co-clustered, indicat-
ing that not all SRE-containing genes were regulated iden-
tically by the three LC-PUFA diets. Overall, the number of
regulated genes with SREs and PPREs indicates the
breadth of molecular responses to dietary LC-PUFA, many
of which appear to be co-orchestrated not only by these
two transcription factors, but by additional elements as
well.
Hepatic SREBP-1 was down regulated with FISH and
FUNG+FISH, but importantly, not affected with FUNG (-
1.1, -2.1*, -1.8*). Thus, chronic AA feeding alone does not
appear, in our experiments, to interact with the SREBP-1
signaling cascade. It is not clear how AA is handled differ-
ently in the liver to prevent its interaction with SREBP. The
probe set in the Affymetrix Murine 11 k chip could not dif-
ferentiate between the -1a and -1c splicing variants of
SREBP-1. There was however high sequence identity
(93%) between the probe set sequence and rat ADD1 mR-Lipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/2
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NA, the murine homologue of human SREBP-1c. The
SREBP-1c/ADD1 isoform regulates transcription of genes
involved in FA biosynthesis and desaturation [37].
SREBP-1c, in addition to interacting with SREs, binds E-
box containing promoters [38]. E-box containing promot-
ers were not examined so the current data analysis could
have underestimated SREBP-1-linked effects. Some E-box
or bHLH binding factors activate the same genes as
SREBP-1. For example, both upstream stimulating factor
(USF; an E-box binding factor) and SREBP bind the FA
synthase (Fasn) E-box [38]. Hepatic Usf2 transcription
was significantly down regulated with FISH, but not af-
fected by FUNG or the combination diet using microar-
rays, but this result could not fully be confirmed using RT-
PCR (1.2, -5.6*, 1.1 with microarray; 2.5, -1.1, 2.0 with
RT-PCR).
The NF-Y transcription factor adds further complexity to
transcriptional regulation since it can interact and modu-
late the expression of SREBP-1c target genes containing Y-
box motifs, such as those found in Fasn [37]. Mutating the
NF-Y binding site in Fasn relieved LC-PUFA-induced Fasn
down regulation [39]. Nfyb was differentially expressed
after dietary LC-PUFA addition (1.8, -1.6, 1.6). Although
no significant changes were observed between dietary
treatments and control diet, a significant difference was
observed between the FUNG and FISH diets. Thus, LC-
PUFA could have induced a joint SREBP-1c/NFY effect on
common promoter elements.
Hepatic nuclear factors (HNFs)
Hepatic nuclear factors have been recognized to be tran-
scription factors mediating the transcription of a variety of
genes putatively involved in energy metabolism. HNFs
may compete with PPARs for binding to DR-1 elements.
Thus, LC-PUFA can activate PPAR/RXR, leading to dis-
placement of HNF4 from PPRE; or be converted to CoA
derivatives, which in turn can suppress HNF4 transcrip-
tional activity. Alternatively, these transcription factors
may respond differently to chronic versus acute adminis-
tration of LC-PUFA.
Hnf4 was not differentially regulated in the current ex-
periment. The related transcription factor HNF3 (winged
helix protein, fork head, Foxa3) was however down regu-
lated -2.0* fold with FUNG+FISH, but not with the indi-
vidual LC-PUFA. HNF3 protein may be involved in
etiology of obesity, hyperlipidemia, and diabetes, by reg-
ulating glucagon transcription, insulin resistance, and
pancreatic  cell function [40,41]. To our knowledge, the
regulation of hepatic HNF3 expression by LC-PUFA has
not been previously reported.
HNF3-signaling may regulate transcription of Pck1 (up
regulated ca. 2* fold with each diet, presently), and G6pc
(differentially regulated in the current experiment) [42].
HNF3 is also reported to increase transcription of several
genes that were not differentially regulated in the present
experiment including, transferrin, tyrosine amino trans-
ferase [43], and IPF-1/PDX-1 [40].
Hepatic fatty acid synthesis
In the cytoplasm, FA synthesis is controlled via Acly, acetyl
CoA carboxylase (ACC), and Fasn. The Acly reaction en-
hances FA synthesis by providing more acetyl CoA and
NADPH substrates and enhancing ACC activity. The mal-
onyl CoA generated in the ACC reaction then inhibits FA
oxidation by reversibly inhibiting Cpt1.
It has previously been shown that the Acly gene in human
cultured hepatic cells has a regulatory region from -61 to -
49 in the 5' flanking region similar to that of Fasn, which
is responsive to insulin and LC-PUFA [44]. In the present
experiment, there was coordinated down regulation of
both Acly (between -1.8* and -8.9* fold regulation for
four different probe sets) and Fasn (-1.9*, -1.3, -5.4*;
FUNG and FISH were not statistically significant from one
another, but each was significantly different with the com-
bination diet). It is intriguing that, in general, both Acly
and Fasn were more strongly down regulated with the
combination diet than the individual LC-PUFA. This syn-
ergy represents just one of the many unexpected findings
revealed with a transcriptomic approach. Although ACC
was not regulated at the transcriptional level, cytoplasmic
citrate (generated from the Acly reaction) is an allosteric
activator of ACC, so less cytoplasmic citrate would lead to
less activation of ACC [45]. Transcript levels of hepatic
acetyl CoA synthetase 1 AMP forming (acetate:CoA ligase
AMP forming; Acas1) were consistently down regulated
by LC-PUFA (-2.5*, -1.7*, -4.4*). This enzyme typically
has specificity for 2–3 C FA chain lengths. In the liver, in-
testine, adipose, and mammary gland, the cytoplasmic
form synthesizes acetyl CoA for lipogenesis [46]. It is reg-
ulated by SREBP-1a, -1c- and -2, as well as SP1 and SP3
binding to GC-boxes; the promoter also contains an E-box
[47]. It is down regulated with fasting, and induced with
re-feeding; such dietary regulation does not exist in
SREBP-1 knockout mice [48]. More generally, acyl CoA
synthase is reported to be PPAR-activated [49]. The ob-
served down regulation is consistent with less acetyl CoA
available for the ACC reaction, as well as a plethora of oth-
er reactions. Overall, it is plausible that both FUNG and
FISH feeding decreased FA synthesis in the current experi-
ment.
Hepatic FA oxidaton
As described above, Acly expression (and possibly ACC
activity) was significantly down regulated by LC-PUFAs,Lipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/2
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likely leading to less FA synthesis. Malonyl CoA inhibits
FA oxidation by reversibly inhibiting Cpt1. Cpt1 transfers
acyl residues from CoA to carnitine in the intermembrane
space of the inner mitochondrial membrane, and has a
regulatory role in controlling hepatic -oxidation [50].
Cpt2 transfers carnitinoyl residues to CoA in the mito-
chondrial matrix for -oxidation. Carnitine acetyltrans-
ferase (Crat) may have the same role as CPT2, but with
specificity for 2–10 C units. Mitochondrial Cpt1 (1.8*,
1.4, 1.7*), Cpt2 (1.6, 1.9*, 1.7*), and Crat (1.4, 3.3*, 1.2)
were all up regulated by LC-PUFA, but the three LC-PUFA
were not identical in this regard. For example, Crat expres-
sion was significantly up regulated 3.3* fold with FISH
treatment, but was less effected with FUNG and the com-
bination diet.
Acyl-Coenzyme A dehydrogenase catalyzes the first step in
mitochondrial  -oxidation, converting acyl-CoA to 2-
trans-enoyl CoA. Isoforms with specificity for short, medi-
um, and long chain FA exist. Medium-chain acyl-Coen-
zyme A dehydrogenase (Acadm) was up regulated,
particularly with the combination diet (1.5, 1.3, 1.7*).
Dienoyl CoA isomerase (also known as 3,5 2,4 dienoyl
CoA isomerase; Ech1 transcripts) converts double bonds
to trans bonds during -oxidation of LC-PUFA. Ech1 was
significantly up regulated with FISH alone (1.1, 1.6*, 1.4),
consistent with the need to isomerize numerous double
bonds during -oxidation. It is not clear why FUNG did
not also up regulate transcripts, as LC-PUFA are generally
reported to up regulate this isomerase [51]. The present
data generally suggest LC-PUFA increased FA oxidation by
down regulating Acly; and up regulating Cpt-1 and -2,
Ech1 and Acadm. However, FUNG, FISH, and
FUNG+FISH did not affect regulation of these transcripts
identically.
Hepatic carbohydrate metabolism
Phosphoenolpyruvate carboxykinase (Pck1) is the rate-
limiting enzyme of gluconeogenesis, and most of its activ-
ity is regulated transcriptionally. Feeding of all three LC-
PUFA diets led to an increase in hepatic Pck1 transcrip-
tion, indicating gluconeogenesis was favored over glycol-
ysis. Specifically, four probe sets with high sequence
similarity to rat Pck1 (accession numbers AA106463,
AA110781, AA080172, AA063800) demonstrated differ-
ential gene expression for the mouse Pck1 homologue.
The signaling pathways affecting Pck1 transcription are
discussed in the section "cAMP signaling/links to carbo-
hydrate metabolism".
G6pc converts glucose-6 phosphate to free glucose during
gluconeogenesis. G6pc was unaffected with FUNG, signif-
icantly up regulated 1.6* fold with FISH (consistent with
up regulated gluconeogenesis), but down regulated -1.9*
fold with the combination diet (1.1, 1.6*, -1.9*). Rat
G6pc has HNF4 consensus binding sites [52]. In HeLa
cells and HepG2 hepatoma cells, PUFA down regulated
G6pc, possibly via inhibition of HNF 4 promoter activity
[52]. In our current mouse experiment, the transcriptional
effects of LC-PUFA on G6pc may thus have been HNF4-
or PPAR mediated.
Hepatic cAMP signaling/links to carbohydrate metabolism
cAMP is an important signaling molecule that can be
found in specific cellular domains [53]. Levels are control-
led through synthesis via adenylate cyclase, and degrada-
tion via phosphodiesterases (PDEs). Calmodulin PDEs
(CaM-PDEs) are sensitive to calmodulin and calcium up
regulation [54]. cAMP can then affect cell signaling via in-
teractions with the regulatory subunits of cAMP activated
kinases, including protein kinase A, leading to their sub-
sequent activation, and via binding of cAMP response el-
ement binding proteins (CREBs) to cAMP response
elements (CREs) or cAMP response units (CRU) consist-
ing of CREs.
In the liver, cAMP regulates Pck1 transcription via the
binding of CREB, as well as CCAAT/enhancer binding
protein (C/EBP), to the CRU. The Pck1 promoter can thus
exist in altered states of cAMP responsiveness, depending
on the transcription factors bound to CRU elements [55].
In hepatocytes, SREBP-1c can block transcriptional induc-
tion of cAMP on PEPCK-C metabolic action [56].
In the present study, liver Cam-Pde 1c was not regulated
by FUNG and FISH feeding alone, but was significantly up
regulated 6.0* fold with FUNG+FISH together. A calcium/
calmodulin-dependent protein kinase 2 (CKII; Camk2b)
was not affected with FUNG feeding or the combination
diet, but was significantly down regulated -7.6* fold with
FISH alone. CKII is a calmodulin target in the brain, in-
volved in synaptic plasticity. In the liver, CKII may be as-
sociated with SAG protein (sensitive to apoptosis gene)
and phosphorylate it. SAG in turn has a role in preventing
oxidation by inhibiting cytochrome c release and caspase
activation. Further, CKII may activate CPT-1 via cytoskel-
etal phosphorylation of cytokeratin. Thus, an activation of
CKII may lead to increased -oxidation and antioxidant
protection. Feeding of all three LC-PUFA diets led to an
approximately 2* fold increase in hepatic Pck1 for each
probe set identified.
Overall, LC-PUFA may up regulate Pck1, the rate-limiting
enzyme in gluconeogenesis, via cAMP-, SREBP-1- and/or
PPAR-signaling [57]. This has the overall effect of limiting
fat accumulation and shunting metabolic flux to glucone-
ogenesis. In a molecular sense, FUNG and FISH feeding
mimics (or accentuates) the fasted metabolic state.Lipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/2
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Hepatic Cytochrome p450 metabolism of LC-PUFA
There are at least 17 cytochrome p450 gene families
(Cyps), with four hepatic types (Cyps 1–4) that metabo-
lize foreign compounds and lipophilic substrates, includ-
ing hormones, FAs, drugs and xenobiotics. Cyp 1
transcription is activated when cytosolic hydrocarbons ac-
tivate the Ah receptor which then translocates to the nu-
cleus and heterodimerizes with Arnt, leading to binding
to an upstream xenobiotic response element on Cyp 1.
Cyps 2–4 are induced through nuclear hormone recep-
tors. Phenobarbitol and phenobarbitol-like substances ac-
tivate CAR-RXR heterodimers (CAR, constitutive
androstane receptor), that bind DR-4 response elements
on the Cyp 2 promoter. Cyps 3 and 4 are activated by PXR-
RXR (PXR, pregnane X receptor) and PPAR-RXR, respec-
tively, also binding DR-4 response elements in both cases.
Nine hepatic cytochrome p450 family members were dif-
ferentially regulated by LC-PUFA (Cyp1a2, Cyp2a4,
Cyp2b9, Cyp3a11, Cyp3a16, Cyp4a10, Cyp4a14, Cypf13,
and Por). Two broad clusters (hierarchical clustering
alone) and 3 specific clusters (hierarchical- and k-means
clustering) of co-expression exist within this subset, indi-
cating transcriptional co-regulation (Table 2). Further-
more, additional specific clusters were close to each other,
indicating only a fine split in expression behavior across
diets.
Cyps 4a-10, -12, and -14 are specifically involved in /-
1 FA hydroxylation [37]. Cyp4a10 (2.7*, 4.7*, 3.0* with
microarray; 15.0*, 18.8*, 6.8* with RT-PCR) and
Cyp4a14 (8.0*, 19.3*, 2.6) were both up regulated by LC-
PUFA. The murine P450 4a14 is highly homologous to rat
4A2 and 4A3. Rat 4A2 and 4A3, and murine 4a10 are re-
ported to /-1 hydroxylate C12:0 and 20:4n6, whereas,
murine 4a14 hydroxylates only C12:0 [58]. Levels of hy-
droxylated FA were not examined. Changes in other he-
patic cytochrome p450 genes are included in Table 2.
Hepatic desaturation of LC-PUFA
As previously noted, SCD-1 is an important enzyme
whose transcription is mediated by both PPAR- and
SREBP-mediated signaling [59]. SCD-1 introduces cis
double bonds at position C9 in FA chains. It has preferred
substrate specificity for C18:0, but will also desaturate
other saturated chain lengths. FUNG+FISH showed a sig-
nificant down regulation of transcripts (-1.1, -1.0, -1.8*
with microarray; 2.5*, -1.4, -2.7* with RT-PCR). In this in-
stance, the microarray indicated no change with FUNG;
however, RT-PCR indicated an up regulation. This may be
expected as RT-PCR is more sensitive than microarrays. It
is important to note however, that changes deemed signif-
icant by the microarray were also confirmed to be signifi-
cant by RT-PCR, as is the case for FUNG+FISH induced
changes in Scd1. The transcriptional changes in Scd1 ex-
pression were in some cases consistent with a marker for
apparent decreased enzymatic activity, namely the ratios
of FA in hepatic PL pools with a 9 double bond/same FA
without a 9 double bond (Table 4). For example, in PS/
PI and phosphatidylethanolamine (PE), the ratio of
16:1n7/16:0 and 18:1n9/18:0 was lowest for the
FUNG+FISH diet.
Hepatic elongation of LC-PUFA
There are suggestions in the literature that FA elongation
may also be controlled by transcription factor signaling.
The elongase Elovl2 may contain an SRE, and therefore be
under the transcriptional control of SREBP [35]). Due to
observations in the metabolite data, which suggests a re-
pression of elongase activity, the dietary regulation of
Elovl2 and Elovl3 was focused on.
Table 4: Ratios of FA in hepatic PL pools with a 9 double bond/equivalent FA without a 9 double bond. There was some evidence to 
indicate 9 desaturase activity may have been impaired, as explained in the text. Abbreviations: FA, fatty acid; PL, phospholipid; see 
Table 1 for additional abbreviations. 9 desaturase is also known as stearoyl-Coenzyme A desaturase (Scd1). Groups sharing a super-
script in common are not statistically significant, ANOVA, P < 0.05.
Group SPN PC PS/PI PE Ether PE
16:1n7/
16:0
18:1n9/
18:0
16:1n7/
16:0
18:1n9/
18:0
16:1n7/
16:0
18:1n9/
18:0
16:1n7/
16:0
18:1n9/
18:0
18:1n9/
18:0
Control 0.03b 0.18b 0.05c 1.27b 0.04c 0.09b 0.04c 0.49c 0.50b
FUNG 0.01a 0.08a 0.03b 0.81a 0.03b 0.09b 0.04c 0.37b 0.30a
FISH 0.01a 0.25b 0.03b 1.28b 0.02b 0.10b 0.03b 0.37b 0.49b
FUNG+ 
FISH
0.01a 0.09a 0.02a 0.80a 0.02b 0.06a 0.02a 0.24a 0.23aLipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/2
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Changes in genes with known elongase activity were ex-
amined. The yeast gene Elo1 is associated with elongating
FAs with 14 to 16 C; yet, this activity is often masked by
cytosolic FA synthase activity [60]. Evidence shows Elovl2
elongates FA to 24C; and Elovl3 elongates FA to 26C, with
preference for converting FA from 24C to 26C, in yeast
[61].
The probe set for Elovl2 was down regulated, particularly
with FISH and the combined diet (-1.3, -1.7*, -1.8*), con-
sistent with some of the lipid data described below;
whereas the probe set for Elovl3 was not affected by
FUNG, up regulated with FISH, and down regulated, al-
though not significantly, with the combination diet (-1.2,
1.9*, -1.6). An NCBI BLAST search identified the murine
homologue of yeast ELO2 (Elovl2) to be Ssc2 (Sequence
similarity to Cig30), predominating in liver and testes
[62]; complementation studies in yeast mutants indicated
the functional equivalent of ELO3 (Elovl3) is Ssc1 [35].
Substrates of mouse Ssc2 were AA and EPA (DHA was not
tested) [35]. Thus, FUNG and FISH feeding may transcrip-
tionally regulate their subsequent conversion to elongated
products.
Our metabolic data showed evidence that elongase activi-
ties may have been altered by LC-PUFA feeding. There was
reduced conversion of 18 to 16C FA following LC-PUFA
feeding. Specifically, the ratio of C18:0/16:0 in phosphati-
dylcholine (PC), PS/PI, PE and ether PE was decreased by
FISH (Table 3). The ratio of 18:1n7/16:1n7 in sphingo-
myelin was decreased by FUNG and FUNG+FISH; in PC,
PE, and CL only FUNG feeding decreased the 18:1n7/
16:1n7 ratio. There was also possible reduced conversion
of 20C to 22C FA, and 22C to 24C FA. The ratios of 24:0/
22:0 in sphingomyelin and PS/PI, 24:1n9/22:1n9 in PS/PI
and CL, 22:4n6/20:4n6 in PC, PE, and CL, and 22:5n3/
20:5n3 in PC and PE, were all reduced by FISH, whereas
FUNG had either a neutral effect or partly reversed effects
seen with FISH (with exception of CL 24:1n9/22:1n9 ra-
tio).
Hepatic Lipid Transport of FAs
Transcription factors such as PPARs and SREBPs are also
known to have an effect on various lipid transport genes.
Hepatic Abca1, Abca7 and Abce1 were differentially regu-
lated; however, their roles in the liver are not precisely
known. Several members of the ATP-binding cassette
(ABC) superfamily, such as Abca1, are induced via PPAR
and LXR activation [63]. Abca1 has been shown to play
a role in reverse cholesterol pathways and may be linked
to HDL deficiency in metabolic syndromes [64]. In mac-
rophages, 18:2n6 and AA increased ABCA1 protein degra-
dation without affecting transcriptional levels [65]. In the
current study, Abca1 was significantly decreased by FUNG
and FISH.
FA translocase (Cd36) was significantly up regulated with
FISH alone (-1.1, 2.4*, -1.5). Cd36 co-clustered with E-
FABP, Apoe, Apoc1, and Abce1 transcript, all involved in
FA and sterol transport. CD36 protein mediates long
chain free FA uptake in adipocytes and other tissues, in-
cluding liver. In murine pre-adipocytes, it is transcription-
ally up regulated by long chain free FAs via a PPAR-
mediated process [66]. Approaches using antisense tech-
nology, null mice, transgenic mice, and microarrays re-
vealed important additional roles of CD36 protein as a
receptor for thrombospondin, collagen type I, and oxi-
dized LDL on macrophages [67]. The up regulation of
Cd36 with FISH, and antagonism in presence of FUNG,
merits further study.
FA binding proteins (FABPs) are small cytosolic proteins
with virtually identical backbone structures that facilitate
the solubility and intracellular transport of FAs. E-FABP is
found in liver and other organs [68], but it has been most
studied in psoriatic skin lesions [69] where it has putative
roles in FA cytoplasmic transport, skin barrier function
and keratinocyte differentiation [70]. Although links be-
tween PPARs and E-FABP have not currently been identi-
fied, this gene clustered with other known PPAR-affected
genes suggesting a possibly important regulatory link. Pu-
rified E-FABP has five fold higher affinity for 18:0, than for
18:1n9 and 20:4n6 (22:6n3 not studied) [69]. Herein, he-
patic E-FABP expression (Fabp5 transcript) was down reg-
ulated by all three diets (-5.5*, -8.4*, -13.6* with
microarray; -2.9*, -8.5*, -16.4* with RT-PCR;). The signif-
icance of this large decrease in hepatic expression by both
FUNG and FISH, and particularly the combination of the
two, is a potentially important finding whose physiologi-
cal consequence must be further investigated. Whether
LC-PUFA induces the same decrease in Fabp5 in psoriatic
skin is not known to our knowledge. N3 LC-PUFA, partic-
ularly 20:5n3, are known to be of clinical benefit in treat-
ing psoriasis [71].
Hepatic cholesterol metabolism, ketogenesis, and apolipo-
proteins
Mitochondrial Hmgcs2, which is involved in ketogenesis,
was up regulated, particularly with the combination diet
(1.2, 1.3, 1.6*). Mitochondrial Hmgcs2 is known to be in-
duced by PPAR activation in experiments with hepato-
cytes [72,73]. The cytosolic form involved in cholesterol
biosynthesis was not affected. Fpps was consistently down
regulated (-2.4*, -1.6*, -1.9*) across diets, which could
lead to reduced cholesterol synthesis; cholesterol synthe-
sis and plasma cholesterol levels were not determined.
Oils rich in DHA, such as fish oil, have cholesterol and tri-
acylglycerol lowering properties [74].
LC-PUFA altered expression of various apolipoproteins.
Apolipoprotein C1 (Apoc1) was only down regulatedLipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/2
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with FUNG alone (-1.7*, 1.1, 1.0). Apolipoprotein E
(Apoe) was only up regulated with FISH alone (1.0, 1.5*,
-1.2). There was consistent up regulation with all three
LC-PUFA diets of an EST (expressed sequence tag) highly
similar to human apolipoprotein B-100 (ApoB-100) pre-
cursor (2.1*, 1.9*, 2.0*). Both apolipoprotein C2 (Apoc2;
-1.3, -1.5*, -1.6*) and apolipoprotein A4 (Apoa4; de-
scribed in detail below) were consistently down regulated
across diets.
Apoe and Apoc1, and Apoa4 and Apoc2, were similarly
co-expressed/co-clustered across diets. When clustered
with genes in the more general "transport" category, cate-
gories of co-expressed genes with underlying roles in lipid
and sterol transport were evident. For example, Apoe and
Apoc1 co-clustered with Abce1 and Cd36; and Apoa4 and
Apoc2 co-clustered with Abca1 and Fabp5.
FUNG and FISH alone moderately down regulated
Apoa4, whereas the combination diet resulted in a large
down regulation (-2.6*, -3.2*, -17.2* with microarray; -
1.3, -3.0, -4.9* with RT-PCR). A similar trend was seen for
Apoa4 precursor transcript (-3.2*, -4.2*, -9.7*). ApoAIV
protein is an anti-atherogenic component of high-density
lipoprotein (HDL) particles and is also found in very low-
density lipoproteins and chylomicrons [75]. It is involved
in cholesterol absorption; low-density lipoprotein (LDL)
clearance as a cofactor for hepatic lipase; increasing doli-
chol acylation; and increasing PE, but not PC, hydrolysis.
FUNG and FISH may decrease Apoa4 expression through
PPAR [76,77], and in the current experiment, LC-PUFA
may have affected PPAR transactivation and signaling.
ApoAIV activity could also be affected by diet induced
structural changes to membrane PL in lipoprotein parti-
cles, as Apoa4 intercalates with PC in model membranes
[78]. The biological consequences of reduced Apoa4 tran-
scription, particularly with the combination diet, merits
further investigation. Rodents fed low cholesterol diets, as
in the present study, carry most of their cholesterol in the
HDL fraction, and under these conditions, fish oil feeding
reduces cholesterol from the HDL fraction, so the above
mentioned changes in apolipoproteins, although fascinat-
ing, must be interpreted within the context of the chosen
models.
FISH and FUNG-mediated effects in the Hippocampus
In the present study, 356 differentially expressed genes
were identified in the hippocampus using a 5% LFC mod-
el. The trend in the data was similar to that seen with liver
data, as shown in Figure 1 (see Materials and Methods for
details). These data revealed that the consumption of die-
tary oils led to differences in the expression of a broad
range of hippocampal genes that have been previously in-
dicated to be involved in cell signaling and signal trans-
duction, including cation transport, calcium binding,
protein phosphorylation, protein kinases, and ATP- and
GTP-binding as revealed by examining GO identifiers
across all of the diet-regulated genes (Figure 2). In striking
contrast to the liver, a number of hippocampal LC-PUFA-
induced differentially expressed genes had annotations
suggesting immune related functions, as well as general
defense responses specific to the hippocampus, including:
"MHC-interacting proteins, lymphocyte antigens, immu-
noglobulins, and defense response." Additionally, there
were numerous ontological assignments for genes which
suggested dietary LC-PUFA feeding affected cell cycle con-
trol including the following categories: "cytoskeleton, cell
cycle control, and cell cycle regulator".
In the hippocampus, dietary LC-PUFA activated a differ-
ent set of transcription factors than observed in the liver,
including: nuclear factor of  light chain gene enhancer in
B cells 1 p105 (Nfkb1); nescient helix loop helix 1
(Nhlh1); E2F transcription factor 3 (E2f3); basic tran-
scription factor 3 (Btf3); inhibitor of DNA binding 1
(Idb1); D site albumin promoter binding protein (Dbp);
paired box gene 9 (Pax9); and the ELK1 member of the
ETS oncogene family. Although dietary LC-PUFA activat-
ed numerous transcriptional factors in both liver and hip-
pocampus, it is a noteworthy difference that the
transcriptional signatures for PPAR, SREBP, and HNF
could not be detected in the hippocampal dataset.
The interpretation of all 356 hippocampal transcripts is
beyond the scope of the current manuscript, but all raw
data is deposited at the NCBI gene expression Omnibus
[79]. The present data provides evidence that LC-PUFA
were incorporated into brain and hippocampal tissues (as
previously discussed) and thereby influenced novel sign-
aling pathways via receptor interactions. Some of these
signaling pathways are highlighted below.
Hippocampal signaling pathways affected by dietary LC-
PUFA
Transthyretin signaling
Thyroid hormones including transthyretin are generally
involved in neuronal proliferation and differentiation,
and are required for normal cytoskeletal assembly. Tran-
sthyretin is specifically involved in transporting thyroxine
(T4) and retinol-binding protein in cerebrospinal fluid
and brain serum. AA has been found to bind transthyretin
and inhibit thyroxin associations [80]. Transthyretin may
also sequester  amyloid, thereby having neuroprotective
properties. Dietary FISH had the effect of decreasing Ttr;
whereas, FUNG and particularly the combination diet, in-
creased Ttr (1.6, -1.9*, 2.2*). Similar to our findings in
mice, feeding rats fish oil significantly decreased Ttr ex-
pression in whole brain 2.9 fold [18]. Interestingly, feed-
ing of Ginkgo biloba extract (publicized to affect mental
function) in mice increased hippocampal Ttr [81]. LevelsLipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/2
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of transthyretin, and associations of transthyretin with
thyroxine and retinol-binding protein should be assessed
in future LC-PUFA feeding experiments.
5-hydroxytryptamine signaling
Dietary LC-PUFA may affect 5-hydroxytryptamine (serot-
onin, 5-HT) signaling. Specifically, 20:4 N-acyleth-
anolamine can displace binding of ligands to HT
receptors [82], and displace 5-HT3 receptor currents [83],
and we have previously reported that dietary AA feeding
increased whole brain 20:4 N-acylethanolamine, as a sep-
arate component of the present work [84]. In the present
work, dietary FUNG and FISH, alone or together, in-
creased Htr4 receptor levels (6.5*, 3.8, 4.4). 5-HT4 recep-
tor (Htr4 transcript) increases in expression have been
shown to augment hippocampal acetylcholine outflow,
thereby affecting cognitive processes [85].
Alpha-2,8-sialyltransferase
Hippocampal  -2,8-sialyltransferase (Siat8e) was down
regulated with FISH and the combination diet, but not
with FUNG; difference relative to control was only signif-
icant for the combination diet (1.6, -2.6, -6.4*). Hippoc-
ampal protein kinase C (Prkcd) was slightly down
regulated with the three LC-PUFA diets (-1.6, -1.3, -1.8*).
PUFA feeding can influence PKC activity [86] and one
mechanism of action may be via generation of unique di-
acylglycerol molecular species [87].
Alpha-2,8-linked disialic acid residues are found in glyco-
proteins [88]. During learning, there is a transient increase
in neuronal polysialyation in the dentate gyrus of the hip-
pocampus. This has been associated with selective reten-
tion and/or elimination of synapses that are transiently
overproduced during memory consolidation [89]. In rat
hippocampus, during development, PKC can negatively
regulate polysialyltransferase activity and neural cell ad-
hesion molecule (NCAM) polysialylation state [89].
NCAM is implicated in neural differentiation and cellular
plasticity [90]. Our observed decrease in Prkcd expression
may have affected hippocampal polysialyltransferase ac-
tivity. It is not known if Prkcd regulates expression of
Siat8e.
Proopiomelanocortin (POMC)
POMC is a hypothalamic neuropeptide, and a target for
leptin. POMC is cleaved post-translationally producing
bioactive peptides (adrenocorticotrophin, -endorphin
and -, - and -melanocyte stimulating hormones) that
interact with neurons expressing melanocortin receptors,
leading to appetite suppression [91]. Feeding high fat di-
ets is known to increase Pomc expression [92]. Herein,
FUNG feeding resulted in a 6.0* fold increase in hippoc-
ampal Pomc, whereas FISH and the combination diet had
smaller, non-statistically significant effects (6.0*, 1.6,
1.4). The physiological effect of potentially increasing
POMC protein with FUNG feeding is not known. As a
next step, levels of POMC protein and downstream
POMC peptides should be quantified
Conclusions and key findings
The molecular effects of dietary fish oil fed in reasonable
quantities over prolonged periods has been found in hu-
mans and animals to be related to alterations in health
outcome. In the present study, mice were fed relevant
quantities of fish oil and AA rich fungal oils and the re-
sponses were studied in murine liver and hippocampus
using a combined gene expression- and lipid-profiling
strategy. The simple addition of these oils to the habitual
diet of mice influenced hundreds of gene products [79].
Furthermore, in a striking number of examples, inter-diet
(FUNG vs. FISH vs. FUNG+FISH) and inter-organ differ-
ences in the transcriptional profile were observed, indicat-
ing that the predominant bioactive FAs in fish oil (20:5n3,
22:5n3 and 22:6n3) and AA enriched fungal oil (20:4n6)
do not affect gene transcription identically in the two or-
gans studied.
Hepatic gene transcriptional profiles and ontology classi-
fications indicated that fish oil LC-PUFA likely increased
FA -oxidation and gluconeogenesis, and decreased FA
synthesis. Furthermore, the transcriptional profile ob-
served indicated that these LC-PUFA regulated hepatic en-
ergy processes through the tight coordination of several
critical transcriptional factors. Feeding both LC-PUFA
containing oils mimicked (or accentuated) the fasted met-
abolic state, confirming this aspect of the beneficial health
effects of dietary LC-PUFA for both normal and clinical
populations, and even household pets.
These same conclusions regarding energy expenditure
were reached in experiments assessing enzymatic activi-
ties, and transcriptional changes in rat liver using North-
ern blots, where fish oil feeding: increased palmitoyl CoA
mitochondrial and peroxisomal oxidation rate; increased
Cpt1, Cpt2, 3, 2-enoyl CoA isomerase, and Ech1 expres-
sion and activity; and decreased expression and activity of
FA synthase, malic enzyme, glucose 6-phosphate dehy-
drogenase, and pyruvate kinase, compared to palm and/
or safflower oil feeding [93]. Likewise, in rat white retro-
peritoneal adipose tissue, fish oil feeding also decreased
Fasn expression [94]. Intriguingly, the hormone leptin,
which also acts through SREBP-1 and PPAR, affected
many transcripts similarly to LC-PUFA (e.g., leptin de-
creased Gpam and Apoa4 transcripts; and up regulated
Ech1, mitochondrial Hmgcs2, and Cyp4a14 transcripts
[95].
Chronic feeding of fish and AA-enriched fungal oils
broadly affected genes regulated by PPAR, HNF, andLipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/2
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SREBP-1 in the liver; transcription factors implicated in li-
pid metabolism as well as other processes. Only with fu-
ture studies in which PPAR-specific agonists and
antagonists are included, along with receptor antagonists,
will the precise role of PPAR-signaling in response to LC-
PUFA feeding be elucidated. The overlapping actions/ef-
fects of these various transcription factors present a chal-
lenge that will require tools, such as genomics and
metabolomics, to provide a stepping stone towards the
complete understanding of LC-PUFA metabolism.
There were striking differences in the genes and transcrip-
tional factors activated by LC-PUFA in the liver and hip-
pocampus, despite these organs being metabolically
linked, as AA and DHA cross the blood brain barrier.
There are at least three reasons for these inter-organ differ-
ences. Firstly, the dietary FAs were not identically incorpo-
rated into both tissues, as indicated by tissue lipid
profiling. Secondly, different transcription factors exist
and were activated in the two organs, which would affect
downstream signaling. Thirdly, there is the possibility,
that even when the same transcription factors were acti-
vated in both organs, factors including dimerization part-
ners, multiple binding of various transcription factors,
post-translational modifications, and signaling kinetics
could affect the transcriptional profile.
Currently, nutritional FA recommendations are made
largely by examining levels of key LC-PUFA in plasma;
and less often, red blood cells, platelets, and biopsied tis-
sue. Transcriptional gene profiles have not been consid-
ered in making such recommendations. The present work
convincingly shows the potential importance of examin-
ing transcriptional profiles in addition to FA profiles; and
the importance of examining more than one tissue, in
making such LC-PUFA nutritional and clinical recom-
mendations.
Materials and Materials
Experimental diets
All diets contained 90% fat-free AIN93G rodent diet in
powder form (Lot 9350–5, Dyets, Inc., Bethlehem, PA),
0.4% milk fat, 1.2% palm olein, 1.9% Trisun sunflower
oil, 1.5% soybean oil and 2.1–5.1% medium chain tria-
cylglycerol oil (all of the above ingredients except the
AIN93G were from Nestlé affiliated companies) (Tables 5
and 6). Part of the medium chain triacylglycerol oil in
control diet was replaced with: 1.1% fungal oil (providing
0.5 dietary wt% AA and 1.0en%) in the FUNG diet; 1.9%
fish oil (providing 0.5 dietary wt% DHA and 1.0en%) in
the FISH diet; and 1.1% fungal oil and 1.9% fish oil in the
combined FUNG+FISH diet. The levels of AA and DHA
chosen were similar to that previously shown in rats to af-
fect neurotransmitter levels and behavior [96]; and were
not excessively high, being 2–3 fold higher than that rec-
ommended for human babies who have a slower 6 de-
saturase activity than rodents. Food was maintained at -
80C in daily aliquots under liquid N2, thawed each after-
noon before administration to mice, and uneaten food
was discarded daily.
Mice, feeding, and dissection conditions
Prior to actual experimentation, test dissections were
made on identical mice to perfect the dissection tech-
niques at Porsolt & Partners Pharmacology (Paris,
France).
Male Rj:NMRI mice from Elevage Janvier, Le Genest-Saint-
Isle France, weighing 10–11 g at delivery and 33–51 grams
on experimental d 42, were housed 10 per cage in wire
cages with bedding and normal light cycle. Mice received
ad libitum quantities of distilled water and purified pow-
dered diets (7.5 g/mouse) in ceramic cups (10/group)
from d 1–57 or 58, and were thereafter sacrificed in the
morning by cervical dislocation over these last 2 experi-
Table 5: Dietary composition of the experimental diets. Values represent the weight percent of each component in the diet, wet weight 
basis. Fungal oil was the source of AA; fish oil was the source of DHA. Suppliers are confidential. Fungal and fish oils were replaced with 
MCT (medium chain triacylgylcerols) to provide the same total fat content of each diet.
Diet ingredient Control FUNG FISH FUNG+FISH
Powdered Diet AIN 93, fat free 90.0 90.0 90.0 90.0
Milk fat 0.4 0.4 0.4 0.4
MCT oil 5.1 4.0 3.1 2.1
Palm olein 1.2 1.2 1.2 1.2
Trisun oil 1.9 1.9 1.9 1.9
Soy oil 1.5 1.5 1.5 1.5
Fungal oil rich in AA 0.0 1.1 0.0 1.1
Fish oil rich in DHA 0.0 0.0 1.9 1.9Lipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/2
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mental days. Food was not removed the night before, and
since nocturnal mice are known to eat during the normal
period dark cycle employed, the mice could have been
fasted 0–6 h at sacrifice. Mice were thus not completely
fasted at sacrifice, a complete fast being 12–16 h.
After feeding diets to 10 mice per group, 5 mice were ran-
domly selected for inclusion in hepatic and hippocampal
gene expression analysis. From these 5 mice, livers were
dissected according to standard protocols (Porsolt & Part-
ners Pharmacology, Boulogne-Billancourt, France), which
consisted of carefully dissecting out the liver, rinsing with
70% EtOH to remove adhering blood, trimming of adher-
ing connective tissue with scissors, cutting into 100–150
mg subsections, freezing in liquid N2, and storing at -80C
until gene expression and lipid analysis. From these same
5 mice, the hippocampus was dissected from the mice ac-
cording to standard protocols (Porsolt & Partners Phar-
macology, Boulogne-Billancourt, France), rinsed as
described for livers, cut into 17–50 mg subsections, and
frozen as described for livers. Hepatic and hippocampal li-
pid analysis was performed according to standard meth-
ods at Lipomics, Inc. (U.S.A) on individual mice (n = 5).
Nucleic acid preparation
Liver tissue was extracted from 5 individual mice per
group and extracted separately using Qiagen RNeasy
mini-kits (Basel, Switzerland) according to manufacturer
instructions, except that RNeasy columns were impregnat-
ed with DNase I (Roche, Basel, Switzerland) to remove
any genomic DNA contamination.
For the group fed a control diet, two independent hepatic
pools (n = 2) of 10 	g each were created, consisting of
equal amounts (2 	g) of total RNA from each of the 5
aforementioned mice. This was done to assess measure-
ment variability. Secondly, a separate piece of liver was ex-
cised from three of the individual control mice (n = 3) to
additionally and independently extract a second set of
RNA; these three mice were chosen at random from the
group of five. This second round of extraction was used to
independently assess the variability of normal control
mice housed under the prevailing conditions of the study.
For each of the other dietary groups, a single pool (n = 1)
of 10 	g total hepatic RNA was created for comparison
against the control. Hippocampal RNA was prepared as
described above for hepatic RNA, except only 1 pooled
control RNA sample from 5 mice was prepared; hence
Table 6: Fatty acid composition of the experimental diets. The sources of all oils are given in Table 5. Values represent g FA/100 g total 
FA, following 3 determinations. The FUNG diet contained ca. 5% AA; the FISH diet contained ca. 5% DHA; and the FUNG+FISH diet 
contained ca. 5% of AA and 5% of DHA.
Fatty Acid Control FUNG FISH FUNG+FISH
4:0 + 6:0 0.2 0.4 0.1 0.3
8:0 27.2 21.3 16.9 11.1
10:0 22.9 18.0 14.3 9.4
12:0+13:0+14:0+ 14:1n5+15:0+17:0 1.6 1.6 2.7 2.7
16:0 7.9 9.2 11.9 13.2
18:0 2.3 3.0 3.5 4.2
18:1n9 24.8 25.4 27.0 27.6
18:1n9 trans 0.3 0.3 0.8 0.8
18:2n6 11.4 12.3 11.9 12.8
18:3n6 - 0.3 0.1 0.4
18:3n3 1.0 1.0 1.1 1.1
18:4n3 - - 0.1 0.1
20:0 0.1 0.2 0.3 0.4
20:1n9 0.1 0.1 0.2 0.2
20:2n6 - 0.1 0.1 0.2
20:3n6 - 0.4 0.1 0.5
20:4n6 - 4.7 0.4 5.1
20:5n3 - 0.3 1.1 1.4
22:0+22:1n9+24:0+24:1n9+26:0+unknown 0.3 1.3 1.9 2.9
22:4n6 - 0.1 0.0 0.1
22:5n3 - - 0.4 0.4
22:6n3 - - 5.2 5.2Lipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/2
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there was a total of 4 pooled hippocampal samples, i.e.
one from each of the 4 diets (Control, FUNG, FISH, and
FUNG+FISH). In sum, eight liver samples and four hip-
pocampal RNA samples were hybridized on Affymetrix
GeneChips.
All RNA samples were quantified with the RiboGreen
RNA Quantification Kit (Molecular Probes, Eugene Ore-
gon), then analyzed via agarose gel electrophoresis for in-
tact 18S and 28S rRNA. All study samples were judged to
contain sufficient amounts of high-quality RNA for hy-
bridization to GeneChips. As another quality control
measure, prior to hybridization with Affymetrix Gene-
Chips (Affymetrix, Inc., Santa Clara, CA), we confirmed
that pooled samples gave strong signals using Affymetrix
test chips.
Gene expression analysis using the murine 11k GeneChip
cRNA preparation
For the control diet group, each of three individual mouse
liver RNA samples (n = 3) were hybridized to Affymetrix
GeneChips. For both the control and LC-PUFA diets, 15
	g pooled total RNA was the starting material for hybrid-
ization to the Mu11kA & B GeneChips. Pooled liver con-
trols were evaluated in duplicate on the Affymetrix probe
array cartridge to estimate experimental variation in gene
chip hybridization, as previously described in detail [27].
In all cases, total RNA was converted to biotinylated cR-
NA, hybridized in the Affymetrix probe array cartridge,
stained, and then quantified. First and second strand
cDNA synthesis was performed using the SuperScript
Choice System (Invitrogen AG, Basel, Switzerland), ac-
cording to manufacturer instructions, but using an oligo-
dT primer containing a T7 RNA polymerase binding site.
Labeled cRNA was prepared with the MEGAscript In Vitro
Transcription kit (Ambion, Inc., Austin, TX). Biotinylated
CTP and UTP (Enzo Biochem Inc., NY) were used together
with unlabeled dNTPs in the reaction, and unincorporat-
ed nucleotides were removed with RNeasy columns.
Array hybridization and scanning
cRNA (10 	g) was fragmented at 94C for 35 min in buffer
containing 40 mM Tris-acetate pH 8.1, 100mM KOAc, 30
mM MgOAc. Prior to hybridization, fragmented cRNA in
a 6X SSPE-T hybridization buffer (6X: 1M NaCl, 10mM
Tris pH 7.6, 0.005% Triton), was heated to 95C for 5
min, cooled to 40C and loaded onto an Affymetrix probe
array cartridge. The probe array was incubated for 16 h at
40C at constant rotation (60 rpm), then exposed to 10
washes in 6X SSPE-T at 25C followed by 4 washes in 0.5X
SSPE-T at 50C. Biotinylated cRNA was stained with 10 g/
mL streptavidin-phycoerythrin conjugate (Molecular
Probes) in 6X SSPE-T for 30 min at 25C followed by 10
washes in 6xSSPE-T at 25C. Probe arrays were scanned at
560 nm using a confocal laser scanning microscope
(made for Affymetrix by Hewlett-Packard). Readings from
the quantitative scanning were analyzed with Affymetrix
Gene Expression Analysis Software.
Selection of differentially regulated genes and data analysis
A mathematical method was developed and applied to
the raw GeneChip data for the selection of differentially
regulated genes. This method moves beyond setting a sin-
gle fold change cut-off by considering fold change in the
context of absolute expression [27]. In brief, this method
includes: (A) the determination of the upper 5% of fold
changes within narrow bins of absolute expression levels
to determine a limit fold change (LFC) function; and (B)
subsequent ranking of genes by a combined fold change/
absolute difference calculation. Herein, absolute expres-
sion is referred to as average difference intensity (ADI) in
all mathematical equations. The function describing the
upper 5% of hippocampal and liver data was described
with the following equations: LFChippocampus = 1.36 +
(90/min ADI); and LFCliver = 1.52+(100/min ADI), re-
spectively.
The selection of differentially expressed genes was corrob-
orated in three ways for liver samples: (1) assessing the
measurement variability and (2) assessing individual
mouse variability in order to establish confidence inter-
vals with which to calculate the significance of differences
with pooled diet response groups and (3) confirmation by
RT-PCR for a sub-selection of genes. Replicate analysis es-
tablished that all genes selected by this method also laid
above a more conventional 99.9% confidence interval,
when compared to the variation of pooled replicates (n =
2). Subsequent analysis of the variation between individ-
ual mice (n = 3) indicated that this variation is compara-
ble to the pooled variation and that all genes selected as
differentially expressed lied above the 99.0% confidence
interval for individual mouse variability. The gene expres-
sion means of the three individual mice were calculated
and compared to pooled data in a scatter plot. A correla-
tion co-efficient of 0.93 was obtained indicating that the
pools are accurate representations of the individual mice
used to create them. Lastly, validation studies showed up
to 85.7% concordance of microarray data with real time
polymerase chain reaction (RT-PCR) across the range of
absolute expression for specific genes selected as differen-
tially regulated [27]. All RT-PCR data, including informa-
tion about the low false positive rate, for all of the liver
samples mentioned in the present work, can be found in
the aforementioned reference.
The 5% LFC method indicated that 513 genes in the hip-
pocampus and 489 genes in the liver were differentially
regulated by LC-PUFA from the original 13,179 genes rep-
resented on the Mu11K Affymetrix GeneChip. Absence/Lipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/2
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presence calls were not considered a priori in selecting sig-
nificantly regulated genes, but were a post-selection crite-
rion. After removing those genes that were identified as
absent across all dietary conditions, 356 hippocampal and
329 hepatic differentially expressed probe sets remained
in the list for further analysis and interpretation. Of these,
221 and 214 genes represented annotated sequences in
the hippocampus and liver, respectively.
Fold changes are always listed in the respective order:
FUNG, FISH, and FUNG+FISH without repeating these la-
bels; and negative signs indicate down regulation. To de-
termine if the ADI for a treatment group was significantly
different from the control diet, the 5% LFC best-fit equa-
tions were utilized: LFChippocampus = 1.36 + (90/min
ADI); LFCliver = 1.52+(100/min ADI). Groups significant-
ly different from the control, as determined by a pair-wise
comparison, are labeled with an asterisk in the text and
Table 2. The mathematical model utilized also selected
some genes due to significant differences between experi-
mental treatments, even when no significant differences
versus the control were observed. For reasons of simplici-
ty, significant differences between experimental treat-
ments are not indicated in Table 2, but are discussed in the
text.
Data analysis
Selected genes were grouped by expression patterns
through a combined k-means and hierarchical clustering
approach (Spotfire, Inc., Sommerville, MA) by setting the
maximum number of clusters in either method to 5 (a
compromise between not having too many or too few
clusters) and then graphing on a 2-D gene plot (Figures
not shown; hierarchical cluster numbers (h1-h5), and k-
means cluster number (k1-5) included in Table 2). Genes
were then annotated using gene ontology (GO) classifica-
tions; a dynamic, structured, yet precisely defined system
which characterizes genes based on defined categories of
molecular function, biological process, and cellular com-
ponent [28]. Finally, genes were assigned names through
NCBI Locuslink (Table 2).
Gene Confirmation
A subset of the genes selected by the 5% LFC model were
examined by RT-PCR using SYBR® green dye (Molecular
Probes) which interacts with double-stranded nucleotide
sequences. Data represented means of triplicates for each
experimental treatment using pooled RNA samples (n =
5). Amplification was performed using an ABI 5700 ma-
chine (Applied Biosystems, Foster City, CA, USA) with a
hot start at 95C for 10 minutes, followed by 40 cycles of
95C for 15 s and 60C for 1 min for denaturation, an-
nealing and elongation. Data was normalized to -actin
and GAPDH, which were not statistically, differentially ex-
pressed. A students t-test ( = 0.05) was used to confirm
significantly differentially expressed genes following RT-
PCR.
Lipid analysis
Following sacrifice of the animals, the livers (250 mg
piece), hippocampus (from half of the mice), and whole
brains (from the other half of mice) from each animal
were rapidly frozen in liquid N2 and stored at -80C. Each
whole brain weighed between 395–454 mg. A slurry of
each whole brain was made by thawing the tissue samples
at room temperature for the minimum time necessary,
adding 12.6 mL of CHCL3:MeOH (2:1, v/v), briefly ho-
mogenizing on ice, and re-freezing the samples under N2
at -80C (concentration was ca. 30 mg brain/mL solvent).
Livers, hippocampus, and whole brain (4 individual sam-
ples/tissue) were quantitatively analyzed for FA distribu-
tion (	g FA/g tissue) in each PL class, by Lipomics
Technologies, Inc. (West Sacramento, CA). Brain samples
were also separately extracted, and N-acylethanolamines
(NAEs) and monoacylglycerols (MAGs) purified and
characterized as previously described in detail [84].
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